Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

The investigators want to evaluate the Efficay and Safety of Platinum-based Chemotherapy with or without immune checkpoint inhibitors for EGFR/ALK/ROS1 Positive NSCLC who Failed from First-Line Standard Treatment.

Trial Details

NCT ID

NCT05284539

Phase

PHASE2

Sponsor

Hunan Province Tumor Hospital

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab

Locations (sample)

Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.
Age ≥ 18 years.
Histologically or cytologically confirmed, Stage IV NSCLC.
EGFR/ALK/ROS1-sensitive mutations confirmed by an accredited local laboratory, progressed from first line systematic therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →